Replay Conf call - Janssen deal & Replay Webcast - ITP Ph2 & AML Ph1/2 data

2013

ARGX-110, a novel anti-CD70 antibody, meets translational development goals in dose escalation part of Phase Ib cancer study

December 17, 2013

Breda, The Netherlands / Ghent, Belgium – arGEN-X announces that the dose-escalation part of a Phase Ib study with its lead antibody ARGX-110 has met its translational development goals: all pre-specified biological activity measures (e.g. target engagement, effector functions, immune-modulation) were met. The study also showed that ARGX-110 has a favourable safety profile and a dose has been selected to advance into the Phase Ib safety and efficacy expansion cohorts, which will start early in 2014 and are expected to report top-line results approximately 12 months later.

arGEN-X raises EUR 5 million from PMV in extension of EUR 32.5 million series B

November 04, 2013

  • Funds to advance ARGX-113, a novel antibody fragment approach to promote degradation and clearance of disease-causing autoantibodies, towards clinical development

Breda, The Netherlands / Ghent, Belgium – arGEN-X, a clinical stage human therapeutic antibody company, has raised EUR 5 million ($6.8 million) as an extension of its series B financing round from the Flemish investment company PMV as a new investor. arGEN-X’ series B round, which had its first close in December 2011, now totals EUR 32.5 million ($44 million). 

arGEN-X and de Duve Institute/UCL to collaborate on novel immunomodulation therapy in cancer

November 04, 2013

Breda, The Netherlands / Ghent, Belgium – arGEN-X today announced the signing of a research and license agreement with de Duve Institute/UCL (Belgium). Under the terms of the agreement, the parties will closely collaborate to use arGEN-X' SIMPLE Antibody™ technology in validating the biology of a novel cancer immunomodulation target and creating functional leads with therapeutic potential. arGEN-X has an option to develop and commercialize resulting antibody drug candidates on an exclusive basis, from which both parties will share the rewards.

arGEN-X reaches milestone in SIMPLE Antibody™ research and product development collaboration with Shire

September 19, 2013

Breda, the Netherlands and Ghent, Belgium September – arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody™ research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration. 

arGEN-X initiates Phase Ib study of ARGX-111 in cancer

September 17, 2013

  • SIMPLE Antibody™ with unique mode of action addressing c-Met positive tumors

Breda, the Netherlands, and Ghent, Belgium – arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces today the CTA filing of a first-in-man Phase Ib cancer study with ARGX-111, its second proprietary SIMPLE Antibody™ product to enter the clinic this year. 

arGEN-X identifies potent antibody antagonists against complex chronic pain target Nav1.7

September 12, 2013

  • Breakthrough data to be presented during the ‘Discovery on Target’ conference in Boston, MA, USA on September 25, 2013

Breda, the Netherlands and Ghent, Belgium – arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has successfully generated potent antibody antagonists of Nav1.7, using its proprietary SIMPLE Antibody™ technology.

arGEN-X grants license to its NHance™ antibody half-life extension technology

August 06, 2013

  • Meeting the Increasing Demand for Technologies that Enable Antibody Product Differentiation

Breda, the Netherlands – arGEN-X, a clinical stage biopharmaceutical company specialized in the creation and development of highly differentiated human antibody therapeutics, today announces the signing of its second non-exclusive license agreement for its antibody half-life extension technology, NHance™. Both licenses granted to date are with companies dedicated to developing and commercializing antibody-based therapeutics with clear clinical benefits.

arGEN-X to Present at Upcoming Ninth Annual PEGS 2013

April 26, 2013

  • Presentations will highlight significant progress made towards development of novel therapeutic antibodies

Breda, the Netherlands and Ghent, Belgium – arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that Professor Hans de Haard (Chief Scientific Officer) and Dr. Debbie Allen (Senior Director, Business Development) will each present at the Ninth Annual PEGS (Protein Engineering Summit). The event takes place April 29-May 3, 2013 at the Seaport World Trade Center (Boston, MA, USA). 

arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders

April 24, 2013

  • First program based on proprietary ABDEG™ technology to promote degradation and clearance of disease-causing autoantibodies

Breda, the Netherlands and Ghent, Belgium – arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed its second product candidate this year into formal preclinical development.

arGEN-X announces preclinical development of ARGX-112 for dermatology

March 25, 2013

  • ARGX-112 targets IL22R1, a novel target involved in chronic skin inflammation

Breda, the Netherlands and Ghent, Belgium – arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed ARGX-112, its fourth therapeutic candidate, into formal preclinical development.

arGEN-X expands its therapeutic antibody alliance with Shire

January 07, 2013

  • New discovery program initiated within 12 months of collaboration start

Breda, the Netherlands – arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody products, is broadening its therapeutic antibody collaboration with Shire. Initiated in March 2012, the existing alliance is focused on arGEN-X using its SIMPLE Antibody™ discovery platform to create novel human antibody therapeutics addressing diverse rare and unmet diseases being pursued by Shire. 

arGEN-X initiates Phase Ib study of ARGX-110 in cancer

January 07, 2013

Breda, the Netherlands, and Ghent, Belgium – arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announced today the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody™ program to enter the clinic in just three years from initiation of discovery.